Guiding pragmatic treatment choices for rifampicin-resistant tuberculosis in the absence of second-line drug susceptibility testing
- PMID: 37945035
- DOI: 10.1183/13993003.00969-2023
Guiding pragmatic treatment choices for rifampicin-resistant tuberculosis in the absence of second-line drug susceptibility testing
Conflict of interest statement
Conflict of interest: J. Achar reports grants from the Swedish Research Council (2020-02336), outside the submitted work. H. Esmail has participated on advisory boards for Cepheid on the subject of novel molecular diagnostics with no financial or other form of compensation received. C.F. McQuaid reports grants from Bill and Melinda Gates Foundation, and the Unitaid Adherence Support Coalition to End TB (ASCENT) project, outside the submitted work. All other authors have no potential conflicts of interest to disclose.
Comment on
-
Emergence of bedaquiline resistance in a high tuberculosis burden country.Eur Respir J. 2022 Mar 24;59(3):2100621. doi: 10.1183/13993003.00621-2021. Print 2022 Mar. Eur Respir J. 2022. PMID: 34503982 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources